AstraZeneca India receives DCGI's nod to market drug treating breast cancer

The Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with early breast cancer, who have previously been treated with neoadjuvant or adjuvant chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8jY6kSA
via IFTTT